Outpatient combination chemoimmunotherapy for patients with metastatic melanoma: Results of a phase I/II trial

Cancer

Volumn 86, Issue 10, 1999, Pages 2160-2165

  Kashani Sabet, Mohammed ^a,c   Sagebiel, Richard W ^a   Collins, Henry E ^a   Glassberg, Alan B ^a   Allen, Robert E ^b   Leong, Stanley P L ^b   Small, Eric J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Chemoimmunotherapy; Interferon ; Interleukin 2; Metastatic melanoma

Indexed keywords

CHLORPROMAZINE; CISPLATIN; DACARBAZINE; GRANISETRON; INTERFERON; INTERLEUKIN 2; LORAZEPAM; ONDANSETRON; TAMOXIFEN;

ADULT; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; COUGHING; DOSE RESPONSE; DRUG SAFETY; FATIGUE; FEMALE; FEVER; GASTROINTESTINAL TOXICITY; HUMAN; LIVER METASTASIS; LUNG METASTASIS; MALE; MELANOMA; NAUSEA; NEUROTOXICITY; OUTPATIENT CARE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SKIN TOXICITY; SOFT TISSUE CANCER; WEIGHT REDUCTION;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG ADMINISTRATION SCHEDULE; FEASIBILITY STUDIES; FEMALE; HUMANS; IMMUNOTHERAPY; MALE; MELANOMA; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 0033571634     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19991115)86:10<2160::AID-CNCR40>3.0.CO;2-W     Document Type: Article

References (15)

1. Balch CM, Reintgen DS, Kirkwood JM, Houghton A, Peter L, Ang KK. Cutaneous melanoma. In: DeVita VT, Hellman S, Rosenberg SA, et al., editors. Cancer: principles and practice of oncology. 5th edition. Philadelphia: Lippincott, 1996: 1947-94.
2. Cocconi G, Bella M, Calbresi F, Tonato M, Canaletti R, Boni C, et al. Treatment of metastatic malignant melanoma with dacarbazine plus tamoxifen. N Engl J Med 1992;327:516-23.
3. Del Prete SA, Maurer LH, O'Donnell J, Forcier RJ, LeMarbre P. Combination chemotherapy with cisplatin, carmustine, dacarbazine, and tamoxifen in metastatic melanoma. Cancer Treat Rep 1984;68:1403-5.
4. Margolin KA, Liu PY, Flaherty LE, Sosman JA, Walker MJ, Smith JW, et al. Phase II study of carmustine, dacarbazine, cisplatin and tamoxifen in advanced melanoma: a Southwest Oncology Group study. J Clin Oncol 1998;16:664-9.
5. Legha SS, Buzaid AC. Role of recombinant interleukin-2 in combination with interferon-alfa and chemotherapy in the treatment of advanced melanoma. Semin Oncol 1993;20:27-32.
6. Richards JM, Mehta N, Ramming K, Skosey P. Sequential chemoimmunotherapy in the treatment of metastatic melanoma. J Clin Oncol 1992;10:1338-43.
7. Khayat D, Borel C, Tourani JM, Benhammouda A, Antoine E, Rixe O, et al. Sequential chemotherapy with cisplatin, interleukin-2 and interferon alfa-2a for metastatic melanoma. J Clin Oncol 1993;11:2173-80.
8. Legha SS, Ring S, Eton O, Bedikian A, Buzaid AC, Plager C, et al. Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alpha, and interleukin-2 for patients with metastatic melanoma. J Clin Oncol 1998;16:1752-9.
9. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1998;10:1-10.
10. Thompson JA, Gold PJ, Fefer A. Outpatient chemoimmunotherapy for the treatment of metastatic melanoma. Semin Oncol 1997;24(Suppl 4):S4-44-S4-48.
11. Atzpodien J, Lopez-Hanninen E, Kirchner H, Franzke A, Korfer A, Volkenandt M, et al. Chemotherapy of advanced malignant melanoma: sequential administration of subcutaneous interleukin-2 and interferon-alpha after intravenous dacarbazine and carboplatin or intravenous dacarbazine, cisplatin, carmustine and tamoxifen. Eur J Cancer 1995;31A:876-81.
12. Rosenberg SA, Yang JC, Topalian SL, Schwartzentruber DJ, Weber JS, Parkinson DR, et al. Treatment of 282 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA 1994;271:907-13.
13. Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL, et al. Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b. J Clin Oncol 1999;17:968-75.
14. Rusthoven JJ, Quirt IC, Iscoe NA, McCulloch PB, James KW, Lohmann RC, et al. Randomized, double-blind, placebo-controlled trial comparing the response rates of carmustine, dacarbazine, and cisplatin with and without tamoxifen in patients with metastatic melanoma. J Clin Oncol 1996;14: 2083-90.
15. Mitchell MS, Jakowatz J, Harel W, Dean G, Stevenson L, Boswell WD, et al. Increased effectiveness of interferon alfa-2b following active specific immunotherapy for melanoma. J Clin Oncol 1994;12:402-11.